How Long Is the Piece of String? – How Patients Negotiate the Uncertainties of a NET Diagnosis Abstract #1291

Introduction: NET Patient Interviews
Aim(s): The aim was to explore challenges patients with NETs face due to their incurable but slow-growing nature.
Materials and methods: Semi-structured interviews with 30 patients (12 female, 18 male) treated for NETs at a hospital in Queensland, Australia. The data was analysed using NVivo10.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr David Wyld
Keywords: Interviews

To read results and conclusion, please login ...

Further abstracts you may be interested in

#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone
Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Bryan A Chan
Authors: Chan B A, Wyld D, Burge M, Cuneo R, ...
#880 Novel Succinate Dehydrogenase Subunit B Intronic Mutation in an Australian Kindred with Variable Clinical and Imaging Phenotype Necessitating Different Treatment Modalities Including 131-I MIBG and 177-Lutetium DOTATATE
Introduction: SDH B mutation has variable functional imaging phenotype challenging in terms of diagnosis, treatment modalities and follow-up.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Kevin Lee
Authors: Lee K, Conway L, Burge M, Wyld D, ...
Keywords: SDHB, Paraganglioma
#1125 Efficacy of PRRT in Metastatic Neuroendocrine Tumors; A Retrospective Large Single Institutional Study
Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Haamid Jan
Authors: Jan H, Wyld D, Burge M, ...
#1263 Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
Introduction: 68GaDOTA TATE imaging of patients with neuroendocrine tumours has shown that tumour sequestration is a major factor leading to a sink effect that decreases activity concentration in healthy tissues, particularly the renal parenchyma.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Steven Goodman
Keywords: dosimetry, PRRT
#1394 The Difficulties of Response Assessment After Peptide Receptor Radionucleotide Therapy (PRRT): An Unusual Case of Symptomatic Pseudoprogression
Introduction: In previous studies patient symptoms, biochemistry (including chromogranin A) and imaging using RECIST criteria have been used to assess tumour response to PRRT.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Lyle M, Wyld D, Burge M, ...